Glucosamine, a naturally occurring amino monosaccharide, suppresses the ADP-mediated platelet activation in humans

Inflammation Research

Volumn 53, Issue 12, 2004, Pages 680-688

  Hua, J ^a   Suguro, S ^b   Iwabuchi, K ^a   Tsutsumi Ishii, Y ^a   Sakamoto, K ^b   Nagaoka, I ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b Koyo Chemical Co Ltd   (Japan)

Author keywords

ADP; Aggregation; Glucosamine; Platelet; Thrombosis

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; AMINOGLYCOSIDE DERIVATIVE; CALCIUM; GLUCOSAMINE; MONOSACCHARIDE; N ACETYLGALACTOSAMINE; N ACETYLGLUCOSAMINE; PROTEIN P72; PROTEIN TYROSINE KINASE; THROMBOXANE A2;

ARTICLE; BIOLOGICAL MONITORING; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; PROTEIN BINDING; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; AMINATION; BLOOD PLATELETS; CALCIUM; ENZYME PRECURSORS; GLUCOSAMINE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MONOSACCHARIDES; PHOSPHORYLATION; PLATELET ACTIVATION; PLATELET FACTOR 4; PROTEIN-TYROSINE KINASES; RECEPTORS, PURINERGIC P2; THROMBOXANE A2;

EID: 12944297739     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00011-004-1312-y     Document Type: Article

References (41)

1. Crolle G, D'Este E. Glucosamine sulphate for the management of arthrosis: a controlled clinical investigation. Curr Med Res Opin 1980; 7: 104-9.
2. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283: 1469-75.
3. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357: 251-6.
4. Oegema TR Jr, Deloria LB, Sandy JD, Hart DA. Effect of oral glucosamine on cartilage and meniscus in normal and chymopapain-injected knees of young rabbits. Arthritis Rheum 2002; 46: 2495-503.
5. Gouze JN, Bordji K, Gulberti S, Terlain B, Netter P, Magdalou J et al. Interleukin-1β down-regulates the expression of glucuronosyl-transferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1β-mediated effects in rat chondrocytes. Arthritis Rheum 2001; 44: 351-60.
6. Hua J, Sakamoto K, Nagaoka I. Inhibitory actions of glucosamine, a therapeutic agent for osteoarthritis, on the functions of neutrophils. J Leukoc Biol 2002; 71: 632-40.
7. Ma L, Rudert WA, Harnaha J, Wright M, Machen J, Lakomy R et al. Immunosuppressive effects of glucosamine. J Biol Chem 2002; 277: 39343-9.
8. Naik RS, Krishnegowda G, Gowda DC. Glucosamine inhibits inositol acylation of the glycosylphosphatidylinositol anchors in intraerythrocytic Plasmodium falciparum. J Biol Chem 2003; 278: 2036-42.
9. George JN. Platelets. Lancet 2000; 355: 1531-9.
10. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998; 129: 394-405.
11. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999; 353: 227-31.
12. Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. BMJ 2002; 325: 828-31.
13. Bjorkman DJ. The effect of aspirin and nonsteroidal anti-inflammatory drugs on prostaglandins. Am J Med 1998; 105: 8S-12S.
14. Crouch SP, Kozlowski R, Slater KJ, Fletcher J. The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J Immunol Methods 1993; 160: 81-8.
15. Bauch HJ, Ilsemann K, Beeck H, Voss B, Balleisen L. A double antibody sandwich microELISA for measuring human platelet factor 4. Thromb Res 1985; 37: 573-82.
16. 2+ stores: studies using fura-2. Biochem Biophys Res Commun 1986; 139: 308-14.
17. d 7.9 μmol/L) platelet binding sites for ADP and competition by ADP analogues. Blood 1988; 71: 110-6.
18. 3H]-2-methylthio ADP to rat platelets-effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther 1994; 269: 772-7.
19. Clutton P, Folts JD, Freedman JE. Pharmacological control of platelet function. Pharmacol Res 2001; 44: 255-64.
20. Abrams CS, Brass LF. Platelet signal transduction. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, editors. Hemostasis and thrombosis Basic principles and clinical practice, vol. 4. Philadelphia: Lippincott Williams & Wilkins, 2001: 541-59.
21. 3 signaling in platelets. Blood 1999; 93: 2645-52.
22. 3- associated syk in platelets. Biochem J 1999; 338: 677-80.
23. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001; 86: 222-32.
24. Berg JM, Tymoczko JL, Stryer L. Enzymes: Basic concepts and kinetics. Biochemistry. vol. 5. New York: W. H. Freeman and Company, 2002: 189-225.
25. Fenton JI, Chlebek-Brown KA, Peters TL, Caron JP, Orth MW. Glucosamine HCl reduces equine articular cartilage degradation in explant culture. Osteoarthritis Cartilage 2000; 8: 258-65.
26. Towheed TE, Anastassiades TP. Glucosamine therapy for osteoarthritis. J Rheumatol 1999; 26: 2294-7.
27. Charo IF, Feinman RD. Detwiler TC. Interrelations of platelets aggregation and secretion. J Clin Invest 1977; 60; 866-73.
28. Woulfe D, Yang J, Brass L. ADP and platelets: the end of the beginning. J Clin Invest 2001; 107: 1503-5.
29. Holmsen H, Weiss HJ. Secretable storage pools in platelets. Ann Rev Med 1979; 30: 119-34.
30. Zucker MB, Nachmias VT. Platelet activation. Arteriosclerosis 1985; 5: 2-18.
31. 3 and ADP receptors. Blood 2002; 99: 193-8.
32. 2A receptors. J Biol Chem 1999; 274: 29108-14.
33. Savage B, Cattaneo M, Ruggeri ZM. Mechanisms of platelet aggregation. Curr Opin Hematol 2001; 8: 270-6.
34. Savi P, Beauverger P, Labouret C, Delfaud M, Salel V, Kaghad M et al. Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett 1998; 422: 291-5.
35. Savi P, Laplace MC, Herbert JM. Evidence for the existence of two different ADP-binding sites on rat platelets. Thromb Res 1994; 76: 157-69.
36. 1 receptors: evidence for separate receptors stimulated by ATP and ADP on human platelets. Br J Pharmacol 2000; 131: 108-14.
37. Rink TJ, Sage SO. Calcium signaling in human platelets. Annu Rev Physiol 1990; 52: 431-9.
38. Setnikar I, Pacini MA, Revel L. Antiarthritic effects of glucosamine sulfate studied in animal models. Arzneimittelforschung 1991; 41: 542-5.
39. Houpt JB, McMillan R, Wein C, Paget-Dellio SD. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J Rheumatol 1999; 26: 2423-30.
40. Russell AI, McCarty MF. Glucosamine in osteoarthritis. Lancet 1999; 354: 1641.
41. Liang Z, Leslie J, Adebowale A, Ashraf M, Eddington ND. Determination of the nutraceutical, glucosamine hydrochloride, in raw materials, dosage forms and plasma using pre-column derivatization with ultraviolet HPLC. J Pharm Biomed Anal 1999; 20: 807-14.